APLLTD817.00

Alembic Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersAJANTPHARMIPCALABTORNTPHARMALIVUSAKUMSAGARWALEYEADVENZYMESAARTIPHARMMcap ₹16,058 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation272.70.0318.6
+ Finance Costs56.278.893.6
+ Interest Income-2.1-6.0-0.9
+ Dividend Income-1.6-1.1-0.4
+ Fair Value (Gains) / Losses-2.8-0.40.8
+ Unrealised FX (Gain) / Loss-40.224.316.3
+ Other Non-cash Items3.70.221.5
Changes in Working Capital
+ Inventories-168.3-644.6-222.5
+ Trade Receivables — Current39.1-395.07.7
+ Other Financial Assets — Current-9.316.40.4
+ Other Current Assets-8.3-65.4-51.2
+ Trade Payables — Current56.0146.2-49.3
+ Other Financial Liabilities — Current24.0-8.45.3
+ Other Current Liabilities-25.66.94.0
+ Other Non-current Liabilities0.0278.60.0
+ Provisions — Current-4.820.625.3
+ Provisions — Non-current1.52.023.4
Cash from Operating Activities
Profit Before Tax (per I/S)632.8706.3693.7724.6
+ Total Adjustments (incl. Working Capital)190.2-546.9192.7
Cash from Operations (pre-tax)823.1159.4886.4
+ Income Taxes Paid19.971.4103.7
Cash from Operating Activities803.288.0782.7
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)327.5563.6434.6
+ Disp of Fixed Assets11.69.82.2
+ Acq of Intangibles under Development0.00.060.3
+ Acq of Other Long-term Assets0.05.00.0
+ Purchase of Investments (Equity / Debt)8.316.10.0
+ Dividends Received — Investing1.61.10.4
+ Interest Received — Investing2.05.50.7
+ Other Inflows / (Outflows) — Investing0.00.0-14.5
Cash from Investing Activities-320.6-568.4-506.1
Cash from Financing Activities
+ Proceeds from Borrowings0.0765.1165.3
+ Repayment of Borrowings205.40.00.0
+ Payment of Lease Liabilities0.026.624.4
+ Payment of Finance Lease Liabilities25.8
+ Interest Paid49.478.688.1
+ Dividends Paid157.3216.2216.2
+ Other Inflows / (Outflows) — Financing-0.0-0.0-0.3
Cash from Financing Activities-437.9443.7-163.8
Net Changes in Cash (pre-FX)44.7-36.7112.9
Net Changes in Cash44.7-36.7112.9
Closing Cash120.283.5
Reference Items
EBITDA933.41,008.21,118.51,169.0
EBITDA Margin %14.9815.1115.2315.02
Free Cash Flow (CFO − Capex)475.7-475.7348.1348.1
Free Cash Flow to Equity210.9425.3
Free Cash Flow per Basic Share24.20-24.2017.7117.71
Price to Free Cash Flow46.13
Cash Flow to Net Income1.300.151.17
Cash Paid for Taxes19.971.4103.7
Cash Paid for Interest49.478.688.1
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.